TP53 and B-cell chronic lymphocytic leukemia: The MDM2 amplification is also observed in 56% of 60 patients with B-cell CLL, leading to overexpression of MDM2, which consequently contributes to tumorigenicity of CLL via suppressing the activation of p53 signaling.99